Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

d9eacc36-0ae3-41bd-aef6-503f91cb25aa

—

517fb693-84a2-5b7b-a0e0-2b545b2b2193

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.600
  • MYC_TARGETS_V1+0.600
  • G2M_CHECKPOINT+0.500
  • MYC_TARGETS_V2+0.500
  • OXIDATIVE_PHOSPHORYLATION+0.500
  • DNA_REPAIR+0.400
  • UNFOLDED_PROTEIN_RESPONSE+0.400
  • CHOLESTEROL_HOMEOSTASIS+0.300
  • MITOTIC_SPINDLE+0.300
  • MTORC1_SIGNALING+0.300

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.500
  • INTERFERON_GAMMA_RESPONSE-0.300
  • KRAS_SIGNALING_DN-0.300
  • APICAL_JUNCTION-0.200
  • APICAL_SURFACE-0.200
  • HEDGEHOG_SIGNALING-0.200
  • MYOGENESIS-0.200
  • P53_PATHWAY-0.200
  • PANCREAS_BETA_CELLS-0.200
  • ANGIOGENESIS-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SAMN03290906
melanoma-umap@29
——0.870
2ERR2598070
medullo-epn-umap@date-based
fetalfetal0.842
31FB9316D-4674-4D97-A33B-649F53D09487
brain-umap@2
——0.837
4SRR975592
colon-landscapes@1
——0.837
5MDT-AP-3294
medullo-epn-umap@date-based
MedMedulloblastoma0.836
6MDT-AP-0541
medullo-epn-umap@date-based
MedMedulloblastoma0.833
767719D37-8CC2-42B5-AF44-6D5AC258FDB1
brain-umap@2
——0.827
8MNG1011
mng-umap@100
——0.823
9MDT-AP-2180
medullo-epn-umap@date-based
MedMedulloblastoma0.822
10ERR2598051
medullo-epn-umap@date-based
fetalfetal0.822

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.600Inavolisib— uncovered
MYC_TARGETS_V10.600Inavolisib— uncovered
G2M_CHECKPOINT0.500Inavolisib— uncovered
MYC_TARGETS_V20.500Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.500Remibrutinib— uncovered
DNA_REPAIR0.400Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.400Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.300Remibrutinib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
MTORC1_SIGNALING0.300Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.300Inavolisib— uncovered
ANDROGEN_RESPONSE0.200Inavolisib— uncovered
NOTCH_SIGNALING0.200Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.200Inavolisib— uncovered
PROTEIN_SECRETION0.200Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.200Inavolisib— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.100Inavolisib— uncovered
FATTY_ACID_METABOLISM0.100Inavolisib— uncovered